Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic-Reference-Cited by-同舟云学术

Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic

Published:2010-01-13 Issue:14 Volume:2 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Koscielny Serge¹

Affiliation:

1. Department of Clinical and Translational Research, Institute Gustave-Roussy, and Unit of Cancer Epidemiology (Unit 605), National Institute of Health and Medical Research, Villejuif, France.

Abstract

Breast cancer provides a ripe arena for an analysis of why gene signatures devised from microarray data have failed to fulfill their promise.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference23 articles.

1. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray

2. Prediction of cancer outcome using DNA microarray technology: past, present and future

3. Milestone 21 (1995). The microarray revolution: An array of opportunities.;Flintoft L.;Nat. Rev. Genet.,2005

4. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

5. Molecular portraits of human breast tumours

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature;International Journal of Cancer;2024-06-14

2. DNA-based molecular classifiers for the profiling of gene expression signatures;Journal of Nanobiotechnology;2024-04-17

3. Advancing precision prognostication in neuro-oncology: Machine learning models for data-driven personalized survival predictions in IDH-wildtype glioblastoma;Neuro-Oncology Advances;2024-01-01

4. Revolutionizing Breast Cancer Treatment: Harnessing the Power of Artificial Intelligence in Overcoming Drug Resistance;Overcoming Breast Cancer Therapy Resistance;2024

5. Nanomedicine and epigenome: Possible health risks, benefits, and future perspectives;Cancer Epigenetics and Nanomedicine;2024